Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis

Flora McErlane, Michael W Beresford, Eileen M Baildam, S E Alice Chieng, Joyce E Davidson, Helen E Foster, Janet Gardner-Medwin, Mark Lunt, Lucy R Wedderburn, Wendy Thomson, Kimme L Hyrich, Childhood Arthritis Prospective Study (CAPS), Flora McErlane, Michael W Beresford, Eileen M Baildam, S E Alice Chieng, Joyce E Davidson, Helen E Foster, Janet Gardner-Medwin, Mark Lunt, Lucy R Wedderburn, Wendy Thomson, Kimme L Hyrich, Childhood Arthritis Prospective Study (CAPS)

Abstract

Objectives: To investigate the validity and feasibility of the Juvenile Arthritis Disease Activity Score (JADAS) in the routine clinical setting for all juvenile idiopathic arthritis (JIA) disease categories and explore whether exclusion of the erythrocyte sedimentation rate (ESR) from JADAS (the 'JADAS3') influences correlation with single markers of disease activity.

Methods: JADAS-71, JADAS-27 and JADAS-10 were determined at baseline for an inception cohort of children with JIA in the Childhood Arthritis Prospective Study. JADAS3-71, JADAS3-27 and JADAS3-10 were determined using an identical formula but with exclusion of ESR. Correlation of JADAS with JADAS3 and single measures of disease activity/severity were determined by category.

Results: Of 956 eligible children, sufficient data were available to calculate JADAS-71, JADAS-27 and JADAS-10 at baseline in 352 (37%) and JADAS3 in 551 (58%). The median (IQR) JADAS-71, JADAS-27 and JADAS-10 for all 352 children was 11 (5.9-18), 10.4 (5.7-17) and 11 (5.9-17.3), respectively. Median JADAS and JADAS3 varied significantly with the category (Kruskal-Wallis p=0.0001), with the highest values in children with polyarticular disease patterns. Correlation of JADAS and JADAS3 across all categories was excellent. Correlation of JADAS71 with single markers of disease activity/severity was good to moderate, with some variation across the categories. With the exception of ESR, correlation of JADAS3-71 was similar to correlation of JADAS-71 with the same indices.

Conclusions: This study is the first to apply JADAS to all categories of JIA in a routine clinical setting in the UK, adding further information about the feasibility and construct validity of JADAS. For the majority of categories, clinical applicability would be improved by exclusion of the ESR.

Keywords: Disease Activity; Juvenile Idiopathic Arthritis; Treatment.

References

    1. Symmons DP, Jones M, Osborne J, et al. Pediatric rheumatology in the UK: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1996;23:1975–80
    1. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991–4
    1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2
    1. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658–66
    1. Nordal EB, Zak M, Aalto K, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis 2012;71:1122–7
    1. Adib N, Hyrich K, Thornton J, et al. Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. Rheumatology(Oxford) 2008;47:991–5
    1. Hyrich KL, Lal SD, Foster HE, et al. Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. Rheumatology(Oxford) 2010;49:116–22
    1. Nugent J, Ruperto N, Grainger J, et al. The British version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19(4 Suppl 23):S163–7
    1. Nordal E, Zak M, Aalto K, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 2011;63:2809–18
    1. ARMA/BSPAR Standards of Care for Children and Young People with JIA. (cited 21 Mar 2012).
    1. Beresford MW, Cleary AG, Foster HE, et al. Comment on: developing standards of care for patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2010;49:2227–9
    1. Bazso A, Consolaro A, Ruperto N, et al. Development and testing of reduced joint counts in juvenile idiopathic arthritis. J Rheumatol 2009;36:183–90
    1. Fuchs HA, Brooks RH, Callahan LF, et al. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989;32:531–7
    1. Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum 1994;37:470–5
    1. Leeb BF, Andel I, Sautner J, et al. The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum 2007;57:256–60
    1. Ringold S, Bittner R, Neogi T, et al. Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease. Arthritis Care Res 2010;62:1095–102
    1. Magni-Manzoni S, Cugno C, Pistorio A, et al. Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis. Clin Exp Rheumatol 2005;23:421–5
    1. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner